Intezyne's $10M Series A Preferred Round Wins SEBIO's 'Deal of the Year'

TAMPA, Fla. and BELMONT, N.C., Nov. 22, 2017 /PRNewswire/ -- Intezyne, a clinical-stage biopharmaceutical company developing novel anti-cancer therapies that is headquartered at the USF Tampa Bay Technology Incubator, announced that its recently closed $10M Series A Preferred round, l...